Drugs / LTG-321
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07110610 | Sep 2025 → Mar 2026 | — | Latigo Biotherapeutics | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LTG-321 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07110610 ↗ |
| Route | Oral | “LTG-321 Administered Orally” NCT07110610 ↗ |